Sunshine Biopharma (SBFM) Invested Capital (2016 - 2025)
Sunshine Biopharma (SBFM) has disclosed Invested Capital for 14 consecutive years, with $24.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Invested Capital fell 3.35% year-over-year to $24.2 million, compared with a TTM value of $24.2 million through Sep 2025, down 3.35%, and an annual FY2024 reading of $23.5 million, up 10.81% over the prior year.
- Invested Capital was $24.2 million for Q3 2025 at Sunshine Biopharma, down from $25.7 million in the prior quarter.
- Across five years, Invested Capital topped out at $41.9 million in Q2 2022 and bottomed at -$1.2 million in Q3 2021.
- Average Invested Capital over 5 years is $19.6 million, with a median of $22.7 million recorded in 2025.
- The sharpest move saw Invested Capital tumbled 111.57% in 2021, then skyrocketed 10117.97% in 2022.
- Year by year, Invested Capital stood at $211662.0 in 2021, then surged by 10117.97% to $21.6 million in 2022, then fell by 1.94% to $21.2 million in 2023, then grew by 10.81% to $23.5 million in 2024, then grew by 2.97% to $24.2 million in 2025.
- Business Quant data shows Invested Capital for SBFM at $24.2 million in Q3 2025, $25.7 million in Q2 2025, and $22.7 million in Q1 2025.